While I'm not privy to it, my interpretations are that they may have had some discussions around it at, and after Phase 2, however these did not materialise or were under the amounts that were deemed minimal and reasonable. It might also have been at PAR's request as they waited for the 008 results (final readout was end of last year). This exciting new data has only just been submitted and a draft protocol revision has been submitted to base the Stage 2 of Phase 3 on this new data.
One could argue that its a blessing they didnt do a deal too early, we are now further downstream now with more paddling to go....frustrating it is, the SP has fallen out of the bottom of the basket but if it all goes to plan and isn't too rough from here...well lets see how it plays out.
While a regional deal would be a great start and show some commercial validation, now I think it more hinges on FDA certainty and what's the plan going forward.
Personal thoughts expressed.
PAR Price at posting:
24.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)